{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:59:42Z","timestamp":1778561982476,"version":"3.51.4"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["IDDT"],"published-print":{"date-parts":[[2020,12,9]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Coagulase negative Staphylococci (CoNS) are important. The common\nantibiotics used for the treatment of the infections caused by CoNS are penicillin, oxacillin, ciprofloxacin,\nclindamycin, erythromycin, gentamicin, and vancomycin. Linezolid is an oxazolidinone\ngroup of antibiotic with activity against Gram-positive bacteria. It is used for the treatment of serious\ninfections caused by Gram-positive bacteria resistant to other antibiotics, including streptococci,\nvancomycin-resistant enterococci (VRE).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aim and Objective:<\/jats:title>\n<jats:p>This study emphasizes on the judicious use of newer antibiotics to contain\nthe spread of resistance.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>We are discussing five cases of Linezolid resistant Staphylococcus Haemolyticus which\nwere reported in our laboratory during one year from patients with device related infections and\nalso review of literature is being presented for an update.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> In our study, the isolates were resistant to other groups of antimicrobials but susceptible to\nglycopeptides. All the isolates were methicillin-resistant.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Linezolid is approved as an alternative drug to be given for catheter-related bloodstream\ninfections. In earlier studies, linezolid-resistant staphylococci have been reported increasingly\nall over the world. This study is to create awareness amongst clinicians that improper and\nexcessive use of linezolid will make this antibiotic-resistant and thus will be of no help in future,\nso judicious and relevant use of antibiotics needs to be emphasized.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871526519666190807152850","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T12:25:53Z","timestamp":1565180753000},"page":"713-717","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Linezolid Resistance in Staphylococcus haemolyticus - Case Series and Review of Literature"],"prefix":"10.2174","volume":"20","author":[{"given":"Varsha","family":"Gupta","sequence":"first","affiliation":[{"name":"Govt. Medical College and Hospital Microbiology, Chandigarh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neelam","family":"Gulati","sequence":"additional","affiliation":[{"name":"Govt. Medical College and Hospital Microbiology, Chandigarh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3822-8476","authenticated-orcid":true,"given":"Shiwani","family":"Sharma","sequence":"additional","affiliation":[{"name":"Govt. Medical College and Hospital Microbiology, Chandigarh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Gupta","sequence":"additional","affiliation":[{"name":"Govt. Medical College and Hospital Microbiology, Chandigarh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwani","family":"Soni","sequence":"additional","affiliation":[{"name":"Govt. Medical College and Hospital Microbiology, Chandigarh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagdish","family":"Chander","sequence":"additional","affiliation":[{"name":"Govt. Medical College and Hospital Microbiology, Chandigarh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Infectious Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/174160","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T04:51:49Z","timestamp":1607575909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/174160\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,9]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,12,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871526519666190807152850","relation":{},"ISSN":["1871-5265"],"issn-type":[{"value":"1871-5265","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-04-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}